Premium
Protein growth factors as potential therapies for central nervous system demyelinative disorders
Author(s) -
Grinspan J. B.,
Stern J.,
Franceschini B.,
Yasuda T.,
Pleasure D.
Publication year - 1994
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.410360734
Subject(s) - remyelination , growth factor , platelet derived growth factor receptor , central nervous system , biology , fibroblast growth factor , multiple sclerosis , regeneration (biology) , platelet derived growth factor , progenitor cell , basic fibroblast growth factor , microbiology and biotechnology , extracellular , neuroscience , immunology , stem cell , biochemistry , myelin , receptor
Demyelinative diseases are frequently accompanied by loss of oligodendroglia; in such instances, oligodendroglial regeneration must precede remyelination. Recent studies indicate that extracellular proteins such as platelet‐derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) profoundly influence the oligodendroglial lineage. PDGF stimulates the formation of oligodendroglia from partially differentiated progenitor cells, whereas bFGF induces mature oligodendroglia to proliferate and dedifferentiate. Manipulations of the central nervous system concentrations of these and other protein growth factors may prove of therapeutic value in multiple sclerosis.